BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at ...

After closing five deals in the first seven months of the financial year, private-equity backed Entero Healthcare Solutions Ltd is set to acquire two companies which engage in the distribution of ...

US-headquartered global tax services and software provider Ryan will acquire a majority stake in Dhruva Advisors, forming a joint venture in India. Ryan’s senior leadership will join Dhruva’s board, ...

Investing.com -- Entero Therapeutics Inc (NASDAQ:ENTO) stock fell 5.7% after the clinical-stage biopharmaceutical company announced plans for a 1-for-3 reverse stock split to regain Nasdaq compliance.

BOCA RATON - Entero Therapeutics, Inc. (NASDAQ:ENTO), currently trading at $0.63 with a market capitalization of $2.98 million, announced Thursday it will implement a 1-for-3 reverse stock split ...

Para multiplicar un entero por la unidad seguida de ceros se añaden a la derecha al entero tantos ceros como ceros acompañen a la unidad. Por ABC Color La multiplicación por la unidad seguida de ceros ...

Clinical-stage biopharmaceutical company specializing in therapies for gastrointestinal diseases Entero Therapeutics (NASDAQ:ENTO) negotiated and signed a rescission agreement with 100% of the ...

Entero Healthcare Solutions Ltd., a healthcare product distribution platform to help retail chemists compete with new age pharma retailers and quick commerce firms, has announced the introduction of ...

Entero Therapeutics, Inc. has announced a $2 million revolving loan agreement and significant changes to its Board of Directors, appointing three new members designated by the lender, following the ...

BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of ...

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Entero (Nasdaq: ENTO) for possible breaches of fiduciary duty and other violations of law in its transaction with Journey. Click here to learn ...